This review is focused to the selected components of neuronal cytoskeleton and antibodies against them in the cerebrospinal fluid. Their benefits to the estimation of the extent of axonal degeneration and loss in a variety of neurological diseases such as multiple sclerosis, Alzheimer disease, amyotrophic lateral sclerosis, stroke and others are discussed.